Raphas Q1 2026 Revenue Decline
라파스
214260
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Q1 2026 Revenue: 3,663M KRW
- • Q1 2025 Revenue: 4,398M KRW
- • Revenue Decrease: 735M KRW YoY
- • Debt-to-Equity Ratio (Q1 2026): 142%
- • Debt-to-Equity Ratio (Q4 2025): 144%
AI Analysis Summary
Raphas Co., Ltd. reported a revenue of 3,663M KRW for Q1 2026, a decrease from 4,398M KRW in Q1 2025, indicating a 16.7% YoY decline. This was primarily driven by a significant drop in domestic sales of its own brand (ACROPASS), which fell from 1,794M KRW to 580M KRW. While ODM exports increased slightly, overall micro-needle sales decreased. The company's debt-to-equity ratio improved marginally from 144% (Q4 2025) to 142% (Q1 2026). The company is actively developing GLP-1 obesity/diabetes treatment patches and other medical patches, with GLP-1 Phase 1 trials completed in March 2025, aiming for future growth in the medical patch market. However, current financial performance shows a negative trend.
How This Event Is Evaluated
Earnings Evaluation
Earnings events are evaluated by comparing profitability, growth, margin direction, and one-off factors against market expectations.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Revenue and profit growth
- Operating margin direction
- Net income quality
- One-off gains or losses
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.